MAPT and Alzheimer disease: Subsequently, several modified analogues of anorexigenic peptides, which decrease food intake, like prolactin-releasing peptide (PrRP) or glucagon-like peptide 1 (GLP-1), showed promise in alleviating neuropathological changes in the brain connected to AD, such as improved spatial memory, reduced amyloid-beta (Aβ) plaques, Tau pathology and neuroinflammation, and at the same time increased neurogenesis and synaptogenesis in different preclinical rodent models od AD-like pathology (Holubová et al. 2019; Pacesova et al. 2022; Spolcova et al. 2015).